By extension, re-establishing DUSP1 levels—either through CEBPB inhibition or direct DUSP1 upregulation—might represent a viable strategy to restore controlled MAPK signaling and reduce tumor aggressiveness. The gene discussed is DUSP1; the disease is neoplasm.